Moderna vaccine improved melanoma outcomes when paired with Keytruda. The Phase 3 findings broaden the potential of ...

Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced new two-year follow up results from ...

This is a web edition of GBH Daily, a weekday newsletter bringing you local stories you can trust so you can stay informed ...

The Baron Health Care Fund reported performance details for the quarter ended September 30, 2026. Read the full analysis for ...

Moderna's CEO Stéphane Bancel on what's next after the recent success in cancer vaccine, and how that impacts the company's ...

Merck presented its mRNA melanoma vaccine trial data at a European cancer conference this weekend. Results are promising: The vaccine reduces recurrence and death alongside an immunotherapy drug.

Adding vaccine to standard post-surgery treatment reduced risk of melanoma returning by 42% two years after surgery ...

Alphabet, Microsoft and Amazon results to test AI investment optimism as rising oil prices and inflation weigh on markets ...

Merck reports Q3 earnings on Oct. 29 with KEYTRUDA's 2028 patent clock ticking louder, and whether LIPFENDRA, QLEX, and ...

After an overall miss, a subgroup showed a 2+ month survival gain; Pfizer is testing sigvotatug vedotin with Merck's Keytruda ...

Healthcare stocks outperformed as Wall Street fell. See top healthcare winners and losers, Moderna data fallout, and major pharma deals—read now.